Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population

American Journal of Hematology

Volumn 81, Issue 12, 2006, Pages 933-937

  Torres Hernández, José Domingo ^a,b   Cardona, H ^a   Alvarez L ^a   Cardona Maya, W ^a   Castaneda S A ^a   Quintero Rivera, F ^a   Cadavid, A ^a   Bedoya, G ^a   Tobon L ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b Universidad de Antioquia ^*  (Colombia)

Author keywords

Activated protein C resistance; Deep vein thrombosis; Factor V Leiden; Methylenetetrahydrofolate reductase; Prothrombin G20210A; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CHILD; COLOMBIA; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FEMALE; G20210A GENE; GENE; GENE MUTATION; GENETIC DISORDER; GENETIC VARIABILITY; HEREDITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; COLOMBIA; DNA MUTATIONAL ANALYSIS; FACTOR V; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POINT MUTATION; PROTHROMBIN; RISK FACTORS; VENOUS THROMBOSIS;

EID: 33845268445     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20733     Document Type: Article

References (31)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998;158:585-593.
2. Robetorye RS, Rodgers GM. Update on selected inherited venous thrombotic disorders. Am J Hematol 2001;68:256-268.
3. Sandoval C, de la Hoz A, Yunis E. Estructura genética de la población Colombiana. Rev Fac Med Univ Nac Colomb 1993;41:3-14.
4. Carvajal-Carmona LG, Soto ID, Pineda N, et al. Strong Amerind/white sex bias and a possible Sephardic contribution among the founders of a population in northwest Colombia. Am J Hum Genet 2000;67:1287-1295.
5. Ruiz-Arguelles GJ, Gonzalez-Estrada S, Garces-Eisele J, Ruiz-Arguelles A. Primary thrombophilia in Mexico: A prospective study. Am J Hematol 1999;60:1-5.
6. Genoud V, Castanon M, Annichino-Bizzacchi J, Korin J, Kordich L on behalf of the Grupo Cooperativo Argentino de Hemostasia y Trombosis. Prevalence of three prothrombotic polymorphisms. Factor V G1691A, factorII G20210A and methylenetetrahydrofolate reductase (MTHFR) C 677T in Argentina. Thromb Res 2000;100:127-131.
7. Zwiebel W. Venous thrombosis. In: Zwiebel W, editor. Introduction to Vascular Ultrasonography. Philadelphia: W. B. Saunders; 2000. pp 329-345.
8. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997;277:1305-1307.
9. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
10. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden - Effect on thrombosis. N Engl J Med 1996;334:763-768.
11. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344:1162-1163.
12. Dahlback B. Inherited thrombophilia: Resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995;85:607-614.
13. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-917.
14. Mannucci PM. Laboratory detection of inherited thrombophilia: A historical perspective. Semin Thromb Hemost 2005; 31:5-10.
15. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia, Part 1. Thromb Haemost 1996;76:651-662.
16. Ruiz-Arguelles GJ, Poblete-Naredo I, Reyes-Nunez V, Garces-Eisele J, Lopez-Martinez B, Gomez-Rangel JD. Primary thrombophilia in Mexico IV: Frequency of the Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients. Rev Invest Clin 2004;56:600-604.
17. Faioni EM, Franchi F, Bucciarelli FP, et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999;94:3062-3066.
18. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: New mutation (Arg306→Thr) associated with resistance to activated protein C. Blood 1998;91:1140-1144.
19. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998;91:1135-1139.
20. Soria JM, Almasy L, Souto JC, et al. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 2003;101:163-167.
21. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995;90:725-727.
22. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995;91:465-470.
23. Ruiz-Arguelles GJ, Garces-Eisele J, Alarcon-Segovia D, Ruiz-Arguelles A. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1996;7:344-348.
24. Mathonnet F, de Mazancourt P, Denninger MH, Morot M, Benattar N, Giudicelli Y. Role of factor VIII on activated protein C resistance ratio in inflammatory diseases. Br J Haematol 1996;95:423-425.
25. Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996;7:761-765.
26. Souto JC, Coll I, Llobet D, et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 80:366-369.
27. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-708.
28. Franco RF, Santos SE, Elion J, Tavella MH, Zago MA. Prevalence of the G20210A polymorphism in the 3′-untranslated region of the prothrombin gene in different human populations. Acta Haematol 1998;100:9-12.
29. Dilley A, Austin H, Hooper WC, et al. Prevalence of the prothrombin 20210 G-to-A variant in blacks: Infants, patients with venous thrombosis, patients with myocardial infarction, and control subject. J Lab Clin Med 1998;132:452-455.
30. Kluijtmans LAJ, Den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998;79:254-258.
31. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: A meta-analysis of published epidemiological studies. J Thromb Haemost 2005;3:292-299.